BIOATLA INC (BCAB)
US09077B1044 - Common Stock
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
BCAB stock results show that BioAtla beat analyst estimates for earnings per share the fourth quarter of 2023.
BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioAtla (NASDAQ:BCAB) just reported results for the fourth quarter of 2023.BioA...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical...
BioAtla CEO purchases 50K common shares (NASDAQ:BCAB)
BioAtla's CEO Jay Short purchases 50K shares at $2.1382/share, as the stock rises 14.8% on Thursday.
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses ...
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated...
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational...
BioAtla to Participate in the Jefferies London Healthcare Conference
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
Award recognizes Dr. Short’s contribution to science innovation
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
Award recognizes Dr. Short’s contribution to science innovation...
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today provided guidance on near-term milestones and announced that it plans to host a conference call and webcast on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide business highlights.
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
BioAtla to Participate in Upcoming Investor Conferences in August
BioAtla to Participate in Upcoming Investor Conferences in August
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic...
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...